8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 3, 2008
(Date of earliest event reported)

ATS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-18602

Minnesota	41-1595629
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)

3905 Annapolis Lane N.
Minneapolis, Minnesota 55447
(Address of principal executive offices, including zip code)

(763) 553-7736
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 8.01. Other Events.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURE
EXHIBIT INDEX
EXHIBIT 99.1
EXHIBIT 99.2

Item 8.01. Other Events.

On November 3, 2008, ATS Medical, Inc. (“ATS” or the “Company”) issued a press release to announce the completion of the final feasibility milestone in the development of the ATS Forcefield^TM technology. The animal feasibility study has been completed with positive results regarding the inhibition of platelet adhesion on mechanical heart valve prostheses. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference. Images of the ATS Forcefield study results are furnished as Exhibit 99.2 hereto and are incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
99.1	Press Release of ATS Medical, Inc. dated November 3, 2008.
99.2	Images of ATS Forcefield study results.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATS MEDICAL, INC.
By:	\s\ Michael R. Kramer
	Michael R. Kramer
	Chief Financial Officer

Date: November 4, 2008

EXHIBIT INDEX

99.1	Press Release of ATS Medical, Inc. dated November 3, 2008.
99.2	Images of ATS Forcefield study results.

EX-99.1

EXHIBIT 99.1

Contacts:	Investors:
Michael Dale, President/CEO	Parice Halbert, CFA
763-553-7736	Westwicke Partners
Michael Kramer, CFO	443-213-0500
763-557-2222

ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results

Minneapolis, MN, November 3, 2008 — ATS Medical, Inc. (NASDAQ: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced completion of the final feasibility milestone in the development of the ATS Forcefield^TM technology. The animal feasibility study has been completed with positive results regarding the inhibition of platelet adhesion on mechanical heart valve prostheses.

This technology has been the focus of presentations at the American Society for Artificial Internal Organs Conference (ASAIO) in June and at the European Association for Cardio-Thoracic Surgeons (EACTS) meeting in September. Previously, Dr. Mark Slaughter, Professor and Chief of Cardiothoracic Surgery at the University of Louisville and Jewish Hospital presented his findings in an acute human trial with excellent results. Adding to this foundation of positive results, ATS has just completed a 90-day animal feasibility study that has demonstrated the longer term sustained effect of Forcefield on a functioning mechanical heart valve implanted in the mitral position. Examination of the surviving animals confirmed essentially zero presence of platelets on the surface of the heart valves after 90-days without the use of anti-coagulation treatment.

The combination of in vitro human blood results, acute human study results, and now this longer term functioning heart valve in an animal model supports our view that the novel Forcefield technology will prove effective and broadly applicable. The next steps will be in preparation for human feasibility trials.

“Forcefield is an enabling technology insofar as the biocompatible interface that we create between a device and the bloodstream is the result of controlling the manner by which a person’s blood first interacts with a device. The result is a natural solution and genuinely biocompatible interface between the device and bloodstream. The magnitude of this achievement is one of a kind and we predict will be disruptive in the future to the implantable device marketplace,” said Michael Dale, President and CEO. “The elimination of long term anti-coagulation medication would provide physicians greater therapy options in the selection of device type and most importantly better therapy for their patients.”

Images of ATS Forcefield study results are available for viewing on atsmedical.com using the following link:

http://phx.corporate-ir.net/phoenix.zhtml?c=89111&p=irol-presentations

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot^® Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f^® brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical’s focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus^® annuloplasty products for heart valve repair and ATS CryoMaze™ surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the outcome of pending litigation matters, the integration of the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company’s activities and results, please refer to the Company’s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.

###

EX-99.2

Pristine carbon mechanical heart valve surface, not exposed to blood Carbon mechanical heart valve surface exposed to human blood - complete platelet coverage EXHIBIT 99.2 ATS FORCEFIELD(tm) TECHNOLOGY

ATS Forcefield(tm) treated carbon mechanical heart valve surface, exposed to in-vitro human blood - no platelet adhesion or migration Un-treated carbon mechanical heart valve surface exposed to in-vitro human blood - complete platelet coverage ATS FORCEFIELD(tm) TECHNOLOGY Bench-top human blood flow results

ATS Forcefield(tm) treated carbon surface, exposed to human blood flow during cardio-pulmonary bypass - - no platelet adhesion Un-treated carbon surface exposed to human blood flow during cardio-pulmonary bypass - - complete platelet coverage ATS FORCEFIELD(tm) TECHNOLOGY Acute human clinical study

ATS FORCEFIELD(tm) TREATED ATS OPEN PIVOT(r) HEART VALVE No evidence of thrombus or platelet aggregation ATS FORCEFIELD(tm) TECHNOLOGY Mitral valve replacement in 90 day animal study - no long term anti-coagulant or anti-platelet therapy

ATS ForceField(tm) treated ATS Open Pivot(r) Valve at 100X - - No evidence of platelets on the valve surface ATS FORCEFIELD(tm) TECHNOLOGY Mitral valve replacement in 90 day animal study - no long term anti-coagulant or anti-platelet therapy

Un-treated study control valve - visual confirmation of thrombosis ATS FORCEFIELD(tm) TECHNOLOGY Mitral valve replacement in 90 day animal study